Aytu BioPharma to Report Fiscal 2026 First Quarter Operational and Financial Results on November 13, 2025
Aytu BioPharma (Nasdaq: AYTU) will report its fiscal 2026 first quarter operational and financial results after market close on Thursday, November 13, 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Aytu BioPharma (Nasdaq: AYTU) will report its fiscal 2026 first quarter operational and financial results after market close on Thursday, November 13, 2025. A conference call and webcast to review results and host Q&A is scheduled the same day at 4:30 p.m. Eastern time. Interested parties can join by phone using US dial-in (888) 506-0062 or international +1 (973) 528-0011 with participant access code 240426. The live webcast and archived replay will be available at the provided webcaster link and on Aytu’s Investors site under Events & Presentations. A teleconference replay is available through November 27, 2025 via replay numbers and access code 53111.
Details
News Market Reaction – AYTU
On Nov 6, the first trading day after this news, AYTU closed 1.38% below the previous close.
Data tracked by StockTitan Argus for the Nov 6 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
DENVER, CO / ACCESS Newswire / November 5, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, will report its operational and financial results for its first quarter of fiscal 2026, after the market close on Thursday, November 13, 2025. The Company has scheduled a conference call and webcast that same day, Thursday, November 13, 2025, at 4:30 p.m. Eastern time, to review the results followed by a question and answer session.
Conference Call Details
Date and Time: Thursday, November 13, 2025, at 4:30 p.m. Eastern time.
Call-in Information: Interested parties can access the conference call by dialing (888) 506-0062 for United States callers or +1 (973) 528-0011 for international callers and using the participant access code 240426.
Webcast Information: The webcast will be accessible live and archived at https://www.webcaster5.com/Webcast/Page/2142/53111, and accessible on the Investors section of the Company's website at https://investors.aytubio.com/ under Events & Presentations.
Replay: A teleconference replay of the call will be available until November 27, 2025, at (877) 481-4010 for United States callers or +1 (919) 882-2331 for international callers and using replay access code 53111.
About Aytu BioPharma
Aytu is a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients. The Company's prescription products include EXXUA™ (gepirone) extended-release tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of major depressive disorder (MDD) and treatments for attention deficit-hyperactivity disorder (ADHD). Aytu is committed to delivering our medications through best-in-class patient access programs that help to enable optimal patient outcomes. For more information, please visit aytubio.com or follow us on LinkedIn.
Contacts for Investors
Ryan Selhorn, Chief Financial Officer
Aytu BioPharma, Inc.
rselhorn@aytubio.com
Robert Blum
Lytham Partners
aytu@lythampartners.com
SOURCE: Aytu BioPharma, Inc.
View the original press release on ACCESS Newswire
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.